The cost of cancer care is increasing, with important implicatons for the delivery of high-quality, patent-centered care. In the clinical setng, patents and physicians express a desire to discuss out-of-pocket costs. Nevertheless, both groups feel inadequately prepared to partcipate in these discussions, and perhaps not surprisingly, the integraton of these discussions into clinical practce seems to be the excepton rather than the rule. The resultng neglect of financial issues has the potental to cause unnecessary suffering for oncology patents. In this paper, we review the most relevant literature on financial toxicity in cancer care. In additon, we discuss potental predictors of financial toxicity, and the recent development of instruments to help clinicians and researchers quantfy financial burden.
ASJC Scopus subject areas